Risk of Secondary Cancers After CAR-T Cell Therapy Is Low, According to Large Stanford Medicine Study

Credit: Steve Gschmeissner/Science Photo Library/Getty Images

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers — is low, despite a Food and Drug Administration warning. 

Login Or Register To Read Full Story